论文部分内容阅读
目的:探讨三阴性乳腺癌（triple-negative breast cancer，TNBC）患者癌组织中雄激素受体（androgen receptor，AR）、Ki67的表达及与预后的关系。方法:收集北京市垂杨柳医院2010年1月至2017年12月收治的41例TNBC患者临床资料进行回顾性分析，采用回顾性病例对照研究，另选同期在北京市垂杨柳医院经手术病理确诊的186例非TNBC患者作为对照组。采用免疫组织化学法检测两组患者癌组织中AR、Ki67的表达情况，分析AR、Ki67的不同表达与TNBC患者临床病理特征及预后的关系。本研究统计分析中，呈正态分布的计量资料两组间比较采用n t检验。计数资料采用χn 2检验。生存率采用Kaplan-Meier法进行分析，Long-rank法进行组间比较。n 结果:TNBC组患者癌组织中AR阳性表达低于对照组［46.3%（19/41）与81.2%（151/186）］，两组比较差异有统计学意义（χn 2=21.69，n P0.05）；而两组的TNM分期、组织学分级及淋巴结转移比较差异均有统计学意义（χn 2值分别为9.34、5.71、6.60，n P值分别为0.05）；而两组患者TNM分期、淋巴结转移比较差异均有统计学意义（χn 2值分别为6.03、4.03，n P值分别为0.010、0.040）。AR阳性表达的TNBC患者3年无病生存率高于AR阴性表达患者（80.1%与67.2%），但两者比较差异无统计学意义（χn 2=3.75，n P=0.056）。AR阳性表达的TNBC患者3年生存率高于AR阴性表达患者（94.1%与78.0%），但两组比较差异无统计学意义（χn 2=3.35，n P=0.068）。Ki67阳性表达的TNBC患者3年无病生存率低于Ki67阴性表达患者（61.0%与89.2%），两者比较差异有统计学意义（χn 2=6.53，n P=0.038）。Ki67阳性表达的TNBC患者3年生存率低于Ki67阴性表达患者（76.1%与96.7%），两者比较差异有统计学意义（χn 2=4.01，n P=0.045）。n 结论:与非TNBC患者比较，TNBC患者癌组织中AR表达降低、Ki67表达升高。TNBC患者癌组织中AR阳性表达越高、Ki67阳性表达越低，预后相对较好，可作为评估乳腺癌患者预后的指标。“,”Objective:To investigate the expression of androgen receptor (AR) and Ki67 in cancer tissues of patients with triple-negative breast cancer (TNBC) and its relationship with prognosis.Methods:The clinical data of 41 patients with TNBC treated in Beijing Chuiyangliu Hospital from January 2010 to December 2017 were collected and analyzed retrospectively. In a retrospective case-control study, 186 patients with non TNBC diagnosed by surgery and pathology in Beijing Chuiyangliu Hospital in the same period were selected as the control group. The expression of AR and Ki67 in cancer tissues of the two groups was detected by immunohistochemical method. and the relationship between the different expression of AR and Ki67 and the clinicopathological features and prognosis of TNBC patients was analyzed. In the statistical analysis of this study, the measurement data with normal distribution were compared between the two groups by t-test. Chi square test was used for counting data. The survival rate was analyzed by Kaplan Meier method and compared between groups by long rank method.Results:The positive expression of AR in cancer tissues in TNBC group was lower than that in control group (46.3%(19/41) and 81.2%(151/186)) and the difference between the two groups was statistically significant (χn 2=21.69, n P0.05). There were significant differences in TNM stage, histological grade and lymph node metastasis between the two groups(χn 2 values were 9.34, 5.71 and 6.60, respectively; n P values were 0.05). There were significant differences in TNM stage and lymph node metastasis between the two groups (χn 2 values were 6.03 and 4.03; n P values were 0.010 and 0.040). The 3-year disease-free survival rate of TNBC patients with AR positive expression was higher than that of patients with AR negative expression (80.1% and 67.2%), but there was no significant difference between them (χn 2=3.75, n P=0.056). The 3-year survival rate of TNBC patients with AR positive expression was higher than that of patients with AR negative expression (94.1% and 78.0%), but there was no significant difference between the two groups (χn 2=3.35, n P=0.068). The 3-year disease-free survival rate of TNBC patients with Ki67 positive expression was lower than that of patients with Ki67 negative expression (61.0% and 89.2%) (χn 2=6.53, n P=0.038). The 3-year survival rate of TNBC patients with Ki67 positive expression was lower than that of patients with Ki67 negative expression (76.1% and 96.7%) (χn 2=4.01, n P=0.045).n Conclusion:Compared with non TNBC patients, the expression of AR decreased and the expression of Ki67 increased in TNBC patients. The higher the expression level of AR and the lower the positive expression of Ki67 in TNBC patients, the better prognosis. It can be used as an indicator to evaluate the prognosis of breast cancer patients.